Fresenius Medical Care stock gains 4.5% as outlook narrows
Published on 11/07/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWeekly outlook and operating pressure
- Fresenius Medical Care narrowed its 2026 operating-income outlook after US treatment volumes declined for a third consecutive quarter.
- Transformation savings, share buybacks and progress in US kidney-care technology provide support while investors track treatment growth.
- Third-quarter operating income excluding special items declined year over year, while one-off China strategy costs weighed on reported earnings.
Fresenius Medical Care stock gained 4.53 percent over the week through Friday, November 6, as investors weighed a narrower 2026 profit outlook against efficiency measures and progress in US kidney-care technology. The Xetra close rose from 40.40 euros on Friday, October 30, to 42.23 euros on Friday, November 6.
On Tuesday, November 3, Fresenius Medical Care said it expected 2026 operating-income growth to range from flat to a negative mid-single-digit percentage, compared with its previous range from a negative mid-single-digit percentage to a positive mid-single-digit percentage. The company continues to expect broadly flat revenue growth at constant currency.
US treatment volumes remain central
Reuters reported on November 3 that US same-market treatments declined 1.1 percent in the third quarter, following declines of 0.4 percent in the first quarter and 0.9 percent in the second. The US business accounts for more than half of group revenue, making treatment volumes a key indicator for the earnings outlook.
Third-quarter operating income excluding special items fell 5 percent to 545 million euros from 574 million euros a year earlier, according to Reuters. Reported earnings also absorbed 108 million euros of one-off costs linked to the China strategy overhaul, including the discontinuation of a dialysis system and the exit from peritoneal dialysis.
Trading context for investors
Fresenius Medical Care stock traded at 42.14 euros on Lang & Schwarz at 12:00 CET on Saturday, November 7, 2026, 0.21 percent below the Xetra close of Friday, November 6. The real-time quote of Fresenius Medical Care stock shows the latest weekend indication.
Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- Xetra ticker: FME
- Lang & Schwarz quote: 42.14 euros on November 7, 2026, at 12:00 CET
- Change versus Xetra close: 0.21 percent below 42.23 euros on November 6, 2026
- Weekly Xetra change: 4.53 percent from 40.40 euros on October 30, 2026, to 42.23 euros on November 6, 2026
- 52-week range: 33.24 to 45.90 euros
German healthcare shares traded in a weaker broader market environment, with the DAX market providing the relevant domestic benchmark.
Investors will focus next on whether US treatment volumes stabilize and whether transformation savings can offset reimbursement, regulatory and inflation pressure. More news and analyses on Fresenius Medical Care stock.
Reuters reported the third-quarter operating figures and the revised outlook.
